Analysts Set CG Oncology, Inc. (NASDAQ:CGON) PT at $61.42

Shares of CG Oncology, Inc. (NASDAQ:CGON) have received an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $66.8333.

CGON has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of CG Oncology from $41.00 to $47.00 and gave the stock an “overweight” rating in a research report on Friday, September 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research note on Wednesday, October 8th. Royal Bank Of Canada raised their price target on CG Oncology from $53.00 to $61.00 and gave the company an “outperform” rating in a report on Monday, November 17th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $82.00 price objective on shares of CG Oncology in a research note on Monday. Finally, Wall Street Zen raised CG Oncology from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd.

Insider Activity at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.43, for a total value of $41,430.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James Mulay sold 11,145 shares of the firm’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On CG Oncology

Several large investors have recently made changes to their positions in CGON. Tema Etfs LLC lifted its position in shares of CG Oncology by 19.3% in the fourth quarter. Tema Etfs LLC now owns 36,057 shares of the company’s stock worth $1,497,000 after buying an additional 5,832 shares in the last quarter. SG Americas Securities LLC increased its stake in CG Oncology by 92.7% in the 4th quarter. SG Americas Securities LLC now owns 20,949 shares of the company’s stock worth $870,000 after acquiring an additional 10,077 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of CG Oncology by 321.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock worth $9,179,000 after acquiring an additional 173,785 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of CG Oncology during the 3rd quarter worth approximately $240,000. Finally, Voleon Capital Management LP bought a new position in shares of CG Oncology during the 3rd quarter valued at approximately $410,000. 26.56% of the stock is owned by institutional investors.

CG Oncology Stock Performance

NASDAQ CGON opened at $53.07 on Friday. The business’s fifty day moving average is $42.52 and its 200 day moving average is $36.05. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $57.40. The company has a market capitalization of $4.28 billion, a PE ratio of -26.01 and a beta of 1.35.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.57) EPS for the quarter, hitting the consensus estimate of ($0.57). The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.07 million. On average, sell-side analysts forecast that CG Oncology will post -1.31 EPS for the current year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.